MS
PASG icon

Maven Securities’s Passage Bio PASG Stock Holding History

Maven Securities’s Portfolio PASG Stock Details PASG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-520
Closed -$164K – 557
2020
Q1 		$164K Buy
+520
New +$163K 0.02% 284

Other funds holding PASG

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HCM
Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Maven Securities's PASG Position: Q2 2020 in Review

Maven Securities sold out of Passage Bio (PASG) in Q2 2020, closing a stake of 520 shares — an estimated $164K sold.

Maven Securities first reported a position in PASG in Q1 2020 and held it in 1 quarter. The position peaked at $164K in Q1 2020. 66 funds tracked by Wall St. Rank hold PASG as of Q2 2020.

  • Maven Securities reported no remaining Passage Bio position as of Q2 2020 after selling out during the quarter.
  • Maven Securities sold 520 Passage Bio shares in Q2 2020, an estimated $164K.
  • Maven Securities first reported a position in Passage Bio in Q1 2020 and held it in 1 quarter.
  • Maven Securities's Passage Bio position peaked at $164K in Q1 2020.
  • 66 funds tracked by Wall St. Rank held Passage Bio as of Q2 2020.

Based on Maven Securities's 13F filing for Q2 2020, filed 14 Aug 2020.